-
IMEIK Technology Development Co.,Ltd Acquires Majority Stake in REGEN Biotech via Joint Venture
•
China-based IMEIK Technology Development Co.,Ltd (SHE: 300896) announced the establishment of Imeik International Limited, a joint venture with Aisheng Shourui (HK) Limited. The primary objective of this joint venture is to acquire 85% stakes in South Korea-headquartered REGEN Biotech, Inc. for USD190 million. As part of this transaction, IMEIK will…
-
Huadong Medicine’s V30 Optical Radiofrequency Device Receives NMPA Review Approval
•
China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that the National Medical Products Administration (NMPA) has accepted a market filing for it’s subsidiary Viora Ltd.’s V30 optical radiofrequency therapy device. The Category III medical device is used for various medical aesthetics procedures, including skin tightening, hair removal, and treating vascular…
-
Juvestar and Raziel Therapeutics Launch Phase III Study for RZL-012 in China
•
Juvestar Biotech Co., Ltd., a subsidiary of China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196), and Israel-based Raziel Therapeutics jointly announced the initiation of a Phase III study for RZL-012 in submental fat (SMF) reduction in China. Drug ProfileRZL-012, an injectable lipolytic drug developed by Raziel for…
-
Huadong Medicine’s Ellansé M Filing Accepted by China’s NMPA
•
China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced that its market filing for the injectable polycaprolactone-based dermal filler Ellansé M has been accepted for review by the National Medical Products Administration (NMPA). This marks a significant milestone for the company as it seeks to expand its presence in the…
-
Advaccine Biotechnology’s MICROEPAD Receives FDA Registration Approval
•
China-based vaccine developer Advaccine Biotechnology has announced receiving registration approval from the US Food and Drug Administration (FDA) for its soluble microneedle drug, MICROEPAD. MICROEPAD: A Revolutionary Approach to Skin TreatmentsMICROEPAD, or Dissolvable Microneedle Blemish Patches, is an over-the-counter (OTC) medication designed to treat acne, acne scars, and blackheads, promoting…
-
Uni-Bio Science Group Achieves Milestones in Medical Aesthetics with New Product Approvals
•
China-based Uni-Bio Science Group Limited (HKG: 0690) has announced two significant achievements in the medical aesthetics and skincare fields. The company’s recombinant collagen dressing, co-developed with Chongqing Minji Medical Device Co., Ltd., has been granted a Category II device approval by the National Medical Products Administration (NMPA). Concurrently, its in-house…
-
Fosun Pharmaceutical’s Daxxify Receives NMPA Approval for Cervical Muscle Tone Disorders
•
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced that the National Medical Products Administration (NMPA) has approved another indication for its product Daxxify (daxibotulinumtoxin, RT002). The type A botulinum toxin is now approved for the treatment of adult cervical muscle tone disorders in China. Background on…
-
Sichuan Huiyu Pharmaceutical’s HY-2003 Approved for Clinical Trials by China’s NMPA
•
Sichuan Huiyu Pharmaceutical Co., Ltd (SHA: 688553), a China-based pharmaceutical company, has announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for its Category 2.2 modified drug, HY-2003. This drug is designed to improve moderate to severe contour protrusion caused by subcutaneous fat accumulation…
-
AbbVie’s Allergan Aesthetics Launches Juvéderm VOLUX in China
•
Allergan Aesthetics, a subsidiary of AbbVie (NYSE: ABBV), has announced the official market launch of its Juvéderm VOLUX dermal filler product in China. Juvéderm VOLUX is a hyaluronic acid-based product specifically designed for contouring the lower jaw area. It is used for injection onto the facial periosteum to enhance the…
-
Sihuan Pharmaceutical Sees Aesthetics and Biopharma Growth Amid Overall Revenue Dip
•
Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460), a leading pharmaceutical company in China, has released its financial report for the first half of 2024, highlighting a strategic pivot towards medical aesthetics and biopharmaceuticals. The company’s “medical aesthetics + innovative drug” dual-driven strategy has been instrumental in this transformation. For the…
-
Fosun Pharmaceutical’s Daxxify Receives NMPA Approval for Aesthetic Use in China
•
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced that the National Medical Products Administration (NMPA) has granted market approval for its product Daxxify (daxibotulinumtoxin, RT002). This type A botulinum toxin is now approved for the temporary improvement of moderate to severe eyebrow wrinkles in adults in…
-
Huadong Medicine Expands Global Footprint with Launch of Aesthetic Injection MaiLi in Singapore
•
Huadong Medicine Co., Ltd (SHE: 000963), a Chinese pharmaceutical company, has announced the international expansion of its medical aesthetics portfolio with the launch of its high-end aesthetic injection product, MaiLi, in Singapore. This marks another milestone in the company’s global foray into the medical aesthetics sector. MaiLi is a premium…
-
Sirnaomics Ltd Forms JV with Gore Range Capital to Pioneer Medical Aesthetics Innovations
•
Sirnaomics Ltd (HKG: 2257), a biopharmaceutical company specializing in RNAi therapeutics, has announced the formation of a joint venture named Sagesse Bio, Inc. with US investment firm Gore Range Capital. This strategic partnership is complemented by a patent transfer and license agreement that will see Sirnaomics transferring specific intellectual property…
-
Haohai Biotech’s Sodium Hyaluronate Gel Receives NMPA Approval for Aesthetic Treatments
•
Shanghai Haohai Biology Science & Technology Co., Ltd (HKG: 6826, SHA: 688366) has announced that it has received Medical Device Registration Approval from the National Medical Products Administration for its innovative amino acid cross-linked sodium hyaluronate gel. The product is indicated for injection into the middle to deep layers of…
-
China Medical System Secures Exclusive Rights to Baiyiyuan Biotech’s Implant in Greater China
•
China Medical System Holdings (CMS; HKG: 0867) has entered into a licensing agreement with Shanghai-based Baiyiyuan Biotech, securing exclusive rights to promote, market, and commercialize Baiyiyuan’s decellularized matrix implant across Greater China, including the China mainland, Hong Kong, Macau, and Taiwan. The financial details of the agreement were not disclosed.…
-
Allergan Aesthetics’ Botox Secures New Indication for Masseter Muscle Protrusion in China
•
Allergan Aesthetics, a division of AbbVie (NYSE: ABBV), has announced that it has received approval for a new indication from the National Medical Products Administration (NMPA) for its Botox (botulinum toxin type A) product. The drug is now approved for the temporary improvement of significant or very significant masseter muscle…
-
TÜV Partners with Lancy Co., Ltd’s BRAVOU to Enhance Medical Aesthetics Services in China
•
Technischer Überwachungs-Verein (TÜV), a Germany-based international independent third-party testing, inspection, and certification organization, has entered into a partnership with the medical aesthetics unit of Chinese firm Lancy Co., Ltd (SHE: 002612), known as BRAVOU. In China, medical aesthetics services are categorized as medical care activities, a sector that has been…
-
Hymson Laser’s Mid Infrared Femtosecond Laser Technology Makes Medical Industry Inroads
•
Shenzhen-based Hymson Laser Technology Group Co., Ltd (SHA: 688559) has announced a significant breakthrough with the application of its mid-infrared femtosecond laser technology in healthcare. The company has developed a long wave infrared femtosecond laser (LWIRFS) with a wavelength range exceeding 5 μm, marking a global first in its category.…
-
Huadong Medicine’s Lidocaine-Containing Hyaluronic Acid Gel Accepted for NMPA Review
•
China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced that the National Medical Products Administration (NMPA) has accepted for review the market approval filing for its Category III medical device, MaiLi Extreme, a lidocaine-containing crosslinked sodium hyaluronate gel. This high-end hyaluronic acid product, which received the CE mark in June…
-
Huadong Medicine’s MaiLi Extreme Achieves Clinical Study Milestone for Chin Retraction Treatment
•
China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced that a Chinese clinical study for MaiLi Extreme, an injectable lidocaine-containing sodium hyaluronate by its UK subsidiary Sinclair, has successfully met its primary endpoint, demonstrating good safety data. The study aimed to evaluate the efficacy and safety of MaiLi Extreme injections…
